🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseMASH biomarker panel — need advice

MASH biomarker panel — need advice

carl_compliance Mon, Nov 3, 2025 at 2:44 PM 14 replies 1,207 viewsPage 1 of 3
This thread is more than 7 months old. Information may be outdated. Consider searching for more recent discussions.
carl_compliance
Member
234
1,123
Nov 2024
Raleigh, NC
Nov 3, 2025 at 2:44 PM#1

This is the version of the explanation I wish somebody had given me, written down before I forget what confused me. It is about the baseline and follow-up panel, and it is deliberately narrow — everything I am not confident about is marked as such.

What is actually established

A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin and B12, and a full blood count. That set catches the things that change, the things that explain symptoms, and the things that alter the prescribing decision. Almost everything else on the long circulating lists is either invariant, uninterpretable without a specific question, or an incidental finding waiting to cause an unnecessary workup.

The condition it depends on

Reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.

The practical version

Post reference ranges alongside numbers when you share them. Units differ by country — glucose and lipids especially — and half the confusion in these threads is unit mismatch rather than disagreement.

What I am not sure about

What would genuinely help is knowing what actually belongs on a baseline panel, as opposed to the enormous list that gets pasted around here. Practical detail welcome, however dull — the duller the better.

— carl_compliance · corrections welcome and will be edited into this post with credit
42 12labquiet_amy, emily_PDX, Dr.SleepRoch and 39 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Nov 3, 2025 at 2:54 PM#2
carl_compliance said:
A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin…

That is correct as far as it goes, and here is where it stops going. The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value. One out-of-range result in isolation generates anxiety and unnecessary tests; the same result next to the trend and the rest of the panel usually generates a shrug.

Last edited: Nov 3, 2025 at 7:54 PM
41 11stefan_berlin, Dr.EM_Chicago, pete_RVA and 38 others
Reply Quote Save Share Report
Dr.ObesityMed
VIP Member
3,456
19,234
Nov 2023
Denver, CO
Online
Nov 3, 2025 at 3:04 PM#3
carl_compliance said:
A defensible baseline is short: HbA1c and fasting glucose, a lipid panel with ApoB if you can get it, ALT and AST, creatinine with eGFR, TSH, ferritin…

This is where I part company with the consensus forming above. I would drop the "get everything" instinct further than this thread does. Every extra test is another chance at a false positive, and incidental findings have their own cost in scans, biopsies and worry.

40 10SurmountFan_IN, PeptideChemSF, A1cHero_PHX and 37 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Nov 3, 2025 at 3:14 PM#4

Short answer first, then the reasoning. Quarterly for the first year is convention rather than evidence, and it is defensible for a simple reason: it is roughly the interval over which HbA1c becomes informative again, since it reflects about three months of glycaemia. After the first year, and once doses are stable, annual is reasonable unless something specific is being followed.

Happy to go further on any of that.

Last edited: Nov 3, 2025 at 9:14 PM
39 9NicoleRaleigh, james_edin, FranDenver and 36 others
Reply Quote Save Share Report
KarenAZ_mom
Member
567
2,567
Aug 2024
Scottsdale, AZ
Nov 3, 2025 at 4:04 PM#5
TrialTracker_MD said:
The single most useful discipline is bringing the whole panel to a clinician rather than one flagged value.

Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.

38 8HPLC_Greg, LibrarianMeg, bri_stats and 35 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register